Clinical trials

Ongoing Protocols : click on protocol for inclusion-exclusioncriteria (update 12/04/2017)

NON-SMALL CELL LUNG CANCER

Staging

ASTER 3
The value of surgical mediastinal staging in clinical N1 lung cancer.

19/22 Trial
Randomized controlled trial comparing the performance of 19 gauge versus 22 gauge EBUS-TBNA needles in lung carcinoma.

Locally advanced

PET Boost
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC.

PEARLS (MSD)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.

NICOLAS (ETOP)
A Feasibility Trial Evaluating Anti-PD1 Nivolumab Consolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC

Advanced

LDK378-NIVOLUMAB (Novartis)
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. 

LDK378 (Ceritinib) (Novartis)
Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges.

INC280 (Capmatinib) (Novartis)
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.

ABEMACICLIB – PEMBROLIZUMAB (Lilly)
A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV
Non-Small Cell Lung Cancer.

LXH254, LTT462 (Novartis)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer.

SMALL CELL LUNG CANCER

Hippocampus Avoidance PCI vs PCI
Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial.

STIMULI (ETOP)
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.

MESOTHELIOMA

NINTEDANIB (Boehringer Ingelheim)
Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma.


OTHERS

For further information regarding protocols or clinical trial unit description, please contact the datamanagers:

christel.oyen@uzleuven.be
liesbet.peeters@uzleuven.be
stefanie.lepers@uzleuven.be
evelyne.louis@uzleuven.be